Petvivo Holdings Inc. (OTCMKTS:PETV)
MINNEAPOLIS, MINNESOTA, USA, November 21, 2017 /EINPresswire.com/ — Press Release PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals”
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
PETVIVO RECIEVES UPPIE AWARD FOR “BEST MEDICAL TECHNOLOGIES FOR HUMAN OR ANIMALS”.
PetVivo Holdings, Inc. OTCPINK: PETV (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce receiving the Uppie Award for “Best Medical Technologies for Human or Animals”, category. Prior to the award announcements, Petvivo was nominated for three categories; Best CEO, Best Medical Technologies for Humans or Animals and Best Scientific Medical Products.
“Petvivo continues to move forward. Our product is attracting the attention from both the investment and medical communities. The public is growing more aware of the company as we near our date for commercial production. We want to thank Uptick Newswire and the Uppie Awards for their recognition of our progress”, said Mr. Wes Hayne, CEO of Petvivo Holdings, Inc.
The Uppie Awards are produced by Uptick Newswire, an Investor Relations firm that provides services to publicly-traded micro-cap and nano-tech companies on the OTC, NYSE and CSE exchanges. The awards ceremony took place November 3rd, 2017 at the Flamingo Hotel in Las Vegas, Nevada, and was attended by micro-cap investors, boutique hedge-fund managers as well as local and national media outlets.
Mr. John Lai, the President of Petvivo Holdings, accepted the award, stating, “I want to thank the Academy…. opps, wrong city and speech (laughing). Seriously, I want to thank the Uppie Awards on behalf of the Company. It is an honor to accept this award. We look forward to next year.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
PetVivo Holdings, Inc.
Main: (612) 296-7305
Direct: (763) 443-7272